Study Summary
This trial will compare the effect of adding radiation therapy to the standard care treatment of immunotherapy drugs for metastatic kidney cancer.
- Carcinoma, Renal Cell
- Metastatic Renal Cell Carcinoma ( mRCC)
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: 2 years
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Standard of Care I/N alone
1 of 2
Standard of Care I/N plus primary disease SBRT
1 of 2
Active Control
Experimental Treatment
78 Total Participants · 2 Treatment Groups
Primary Treatment: SBRT + Ipilimumab/Nivolumab · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 20th, 2021
Last Reviewed: November 16th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.